How does 0ABR's PE Ratio compare to its peers?

0ABR is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (25x).

How does 0ABR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0ABR is good value based on its Price-To-Earnings Ratio (16.5x) compared to the European Pharmaceuticals industry average (20.7x).

What is 0ABR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ABR is good value based on its Price-To-Earnings Ratio (16.5x) compared to the estimated Fair Price-To-Earnings Ratio (23.2x).

What is the Fair Price of 0ABR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0ABR (DKK36.25) is trading below our estimate of [[fair value]] (DKK129.42)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

H. Lundbeck (LSE:0ABR) - Stock Price, News & Analysis

0ABR Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

0ABR fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	3/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 72% below our estimate of its fair value

Earnings are forecast to grow 8.57% per year

Earnings have grown 7% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for 0ABR from our risk checks.

H. Lundbeck A/S Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.0b

GSK

LSE:GSK

UK£53.1b

AstraZeneca

LSE:AZN

UK£154.7b

Animalcare Group

AIM:ANCR

UK£143.1m

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	DKK 36.25
52 Week High	DKK 41.70
52 Week Low	DKK 27.55
Beta	0.18
11 Month Change	-7.41%
3 Month Change	-5.84%
1 Year Change	18.31%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	42.66%

Recent updates

Shareholder Returns

	0ABR	GB Pharmaceuticals	GB Market
7D	2.0%	-1.0%	-0.4%
1Y	18.3%	-4.0%	5.6%

Return vs Industry: 0ABR exceeded the UK Pharmaceuticals industry which returned -4% over the past year.

Return vs Market: 0ABR exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is 0ABR's price volatile compared to industry and market?
0ABR volatility
0ABR Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0ABR has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0ABR's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1951	5,800	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
0ABR fundamental statistics
Market cap	DKK 42.66b
Earnings (TTM)	DKK 2.69b
Revenue (TTM)	DKK 21.44b

16.5x

P/E Ratio

2.1x

P/S Ratio

Is 0ABR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0ABR income statement (TTM)
Revenue	DKK 21.44b
Cost of Revenue	DKK 4.37b
Gross Profit	DKK 17.07b
Other Expenses	DKK 14.39b
Earnings	DKK 2.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 05, 2025

Earnings per share (EPS)	2.71
Gross Margin	79.63%
Net Profit Margin	12.53%
Debt/Equity Ratio	15.6%

How did 0ABR perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

26%

Payout Ratio

0ABR Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

LSE:HIK

UK£4.0b

LSE:GSK

UK£53.1b

LSE:AZN

UK£154.7b

AIM:ANCR

UK£143.1m

Price History & Performance

Recent News & Updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

H. Lundbeck A/S Fundamentals Summary

16.5x

2.1x

Earnings & Revenue

Dividends

1.6%

26%